The Meals and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the drug’s second full approval after a 2023 clearance for IgA nephropathy. Travere’s inventory rose 43 % the subsequent day, closing at $43.81.
The DUPLEX Knowledge Behind a Second Approval
FSGS damages the kidney’s filtering models. Protein leaks into urine, and in lots of instances the illness progresses towards kidney failure.
The approval covers sufferers age 8 and older with major, genetic and secondary subtypes of FSGS who wouldn’t have nephrotic syndrome, based mostly on outcomes from the Section 3 DUPLEX trial.
Sufferers on FILSPARI, identified chemically as sparsentan, confirmed a 46 % discount in proteinuria from baseline at week 108, in contrast with 30 % for sufferers on irbesartan, an angiotensin receptor blocker used because the trial’s comparator. The distinction was important at p=0.0299.
Among the many subset with out nephrotic syndrome, the discount reached 48 % in opposition to 27 % for irbesartan, at p=0.0075, and that group additionally gained an estimated 1.1 mL/min/1.73 m² in kidney filtration fee relative to the comparator arm.
Travere estimates greater than 30,000 sufferers in the USA have FSGS with out nephrotic syndrome, a part of a broader pool exceeding 100,000 sufferers throughout FSGS and IgA nephropathy mixed.
Chief Govt Eric Dube referred to as the choice “a historic milestone for individuals residing with FSGS, who for the primary time have an FDA-approved medication for this uncommon and devastating situation”.
Nationwide Kidney Basis President Kirk Campbell famous that sufferers had beforehand relied “on off-label therapies comparable to long-term steroids.” NephCure Chief Govt Josh Tarnoff described the approval as “a life-changing second”.
Two Quarters of Accelerating Gross sales
The approval’s business impact confirmed up nearly instantly. Travere’s first-quarter 2026 report, issued earlier than a full quarter of FSGS prescribing had amassed, already carried indicators of the acceleration to come back.
FILSPARI’s U.S. internet product gross sales reached $105.2 million within the first quarter, an 88 % enhance over the identical interval in 2025.
Whole income got here to $127.2 million, and Travere reported its first quarter of non-GAAP profitability, $4.1 million, alongside a GAAP internet lack of $37.1 million. The corporate held $264.7 million in money, money equivalents and marketable securities as of March 31.
The second quarter confirmed the approval’s fuller impact. FILSPARI’s U.S. gross sales climbed to $141.1 million, up 96 % yr over yr, bringing first-half 2026 gross sales to $246.2 million.
Whole income for the quarter reached $169.6 million, in opposition to $114.4 million a yr earlier, and the corporate logged 2,012 new affected person begin types through the interval. Travere’s inventory rallied 13.4 % on Aug. 5, the day after it launched the outcomes.
Dube described the quarter as one during which “Travere has entered a brand new chapter of near- and long-term progress.” Money and marketable securities climbed to $489.2 million by June 30, practically double the steadiness three months earlier.
Travere didn’t separate the affected person begin determine by indication. The corporate attributed the mixed whole to “the primary months of the FSGS launch and continued progress” in IgA nephropathy.
Buyers don’t but have a clear learn on how a lot of the acceleration got here from the newer approval versus the drug’s older use, a spot that ought to slim as extra quarters of FSGS-specific prescribing accumulate.
Wall Avenue Recalculates the Mannequin
Guggenheim raised its worth goal on Travere to $56 from $54 on April 24, sustaining a purchase ranking. The agency up to date its FILSPARI gross sales mannequin for what it referred to as a broader-than-expected label, one masking major, genetic and secondary FSGS somewhat than a narrower subset.
The be aware estimated roughly 95,000 prevalent FSGS sufferers in the USA, with about 90 % eligible for therapy beneath the permitted label, and projected peak U.S. FSGS income close to $2.2 billion by 2032.
Mixed with the prevailing IgA nephropathy indication, Guggenheim put FILSPARI’s peak U.S. gross sales potential at roughly $3.1 billion, in step with Travere administration’s personal steerage of greater than $3 billion. The agency’s mannequin additionally connected roughly $8 in per-share worth to every further yr of exclusivity FILSPARI holds past 2033.
A Licensing Deal Broadens the Pipeline
Travere used a part of its expanded money place to increase past its two permitted indications. On June 2, the corporate signed an unique licensing settlement with Everest Medicines for civorebrutinib, an experimental BTK inhibitor, masking markets outdoors China and components of East and Southeast Asia.
Travere paid $112.5 million upfront, with further milestone funds that would exceed $1.03 billion tied to growth, regulatory and business targets throughout as many as 5 indications, amongst them major membranous nephropathy, immune-mediated FSGS and minimal change illness.
The businesses described the accompanying royalties as tiered, “starting from excessive single-digit to double-digit percentages” relying on annual gross sales thresholds.
Dube referred to as the drug candidate “a strategic and complementary addition to our uncommon kidney illness portfolio,” and Everest Chairman Yifang Wu stated the businesses can be “advancing civorebrutinib in major membranous nephropathy” collectively.
The place Armistice Capital’s Stake Stands
Armistice Capital has held Travere shares by way of a lot of the drug’s regulatory development. Its place has moved in the wrong way from the inventory worth.
A Schedule 13G filed Could 15, 2026, confirmed Armistice holding 4,897,417 shares, 5.27 percent of the company, down from the 6,724,000 shares, 7.52 %, disclosed in a Nov. 14, 2025, submitting, a discount of roughly 24 % between the 2 disclosures.
That earlier submitting, made 5 months earlier than the FSGS approval, already mirrored a fund trimming its publicity forward of the choice somewhat than including to it.
Different institutional holders occupy bigger positions within the firm. Janus Henderson Group held 10,599,660 shares, 11.90 %, as of the identical Nov. 14, 2025, reporting window used for Armistice’s prior disclosure.
BlackRock held 8,100,461 shares, 9.10 %; Vanguard Group held 6,613,368 shares, 7.43 %; and Macquarie Group held 4,984,333 shares, 5.61 %.
A Schedule 13G covers a passive stake. A 13F stories quarterly holdings no matter intent. The figures describe a degree in every fund’s place, not a single synchronized snapshot of the shareholder base.
The hole in submitting dates is a perform of disclosure timing somewhat than information availability. Quarterly 13F stories are due 45 days after quarter’s finish, whereas a Schedule 13G follows a separate threshold-based and annual modification schedule, which is why Armistice’s most present disclosure arrived in Could somewhat than in keeping with the broader 13F cycle utilized by Janus Henderson, BlackRock, Vanguard and Macquarie.
The precise holdings date behind that 5.27 % determine is just not acknowledged within the submitting abstract reviewed for this text, so whether or not the fund added to or further trimmed the position once FSGS sales began is just not but established within the public report.
How Specialist Funds Commerce Round Binary Catalysts
Armistice’s reduction suits a sample widespread amongst funds constructed round binary regulatory occasions. Companies that focus biotech and pharmaceutical bets, amongst them Baker Brothers Advisors, OrbiMed Advisors, RA Capital Administration, Perceptive Advisors and Vivo Capital, have a tendency to construct positions months forward of an FDA choice date somewhat than within the days beforehand, then resize the place as soon as the result is understood, in accordance with BiopharmaWatch’s evaluation of catalyst-driven biotech buying and selling.
That resizing runs in each instructions. A fund with persevering with conviction could add to a place after a good ruling. A fund that constructed its stake primarily to seize the binary occasion, somewhat than the years of business execution that comply with, has cause to trim and take the achieve as soon as the result resolves.
Guggenheim’s math, an $8 per-share swing for a single yr of added exclusivity, illustrates why the years after an approval can transfer a valuation as a lot because the approval itself.
Two further quarters of accelerating gross sales adopted Travere’s approval. A licensing deal prolonged the pipeline into three new indications, and the corporate’s money place practically doubled inside three months.
Buyers who held by way of the choice and the 2 earnings stories that adopted captured a inventory that gained floor twice, 43 % on the approval itself and one other 13.4 % on the second-quarter outcomes. Armistice’s filings show a fund that had already reduced its exposure earlier than both of these features arrived.
